Enalapril
- Generic Name
- Enalapril
- Brand Names
- Epaned, Vaseretic, Vasotec, Aqumeldi
- Drug Type
- Small Molecule
- Chemical Formula
- C20H28N2O5
- CAS Number
- 75847-73-3
- Unique Ingredient Identifier
- 69PN84IO1A
- Background
Enalapril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor drug class that works on the renin-angiotensin-aldosterone system, which is responsible for the regulation of blood pressure and fluid and electrolyte homeostasis. Enalapril is an orally-active and long-acting nonsulphydryl antihypertensive agent that suppresses the renin-a...
- Indication
Indicated for the management of essential or renovascular hypertension as monotherapy or in combination with other antihypertensive agents, such as thiazide diuretics, for an additive effect.
Indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis.
...
- Associated Conditions
- Diabetic Nephropathy, Hypertension, Symptomatic Congestive Heart Failure, Asymptomatic Left ventricular dysfunction
- Associated Therapies
- -
Pulmonary REsistance Modification Under Treatment With Sacubitril/valsartaN in paTients With Heart Failure With Reduced Ejection Fraction
- Conditions
- Interventions
- First Posted Date
- 2022-08-04
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Clinical Hospital Heliodor Swiecicki of the Medical University of Karol Marcinkowski in Poznań
- Target Recruit Count
- 260
- Registration Number
- NCT05487261
- Locations
- 🇵🇱
Medical University of Bialystok Clinical Hospital, Białystok, Poland
🇵🇱University Clinical Centre in Gdańsk, Gdańsk, Poland
🇵🇱Specialist Hospital in Zabrze, Zabrze, Poland
The Effects of Sacubitril-Valsartan vs Enalapril on Left Ventricular Remodeling in ST-elevation Myocardial Infarction
- Conditions
- Interventions
- First Posted Date
- 2021-06-03
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 376
- Registration Number
- NCT04912167
- Locations
- 🇨🇳
West China Hospital, Chengdu, Sichuan, China
Angiotensin Receptor-Neprilysin Inhibition in Chagas Cardiomyopathy With Reduced Ejection Fraction: ANSWER-HF.
- Conditions
- Interventions
- First Posted Date
- 2021-04-21
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- University of Sao Paulo General Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT04853758
- Locations
- 🇧🇷
Heart Institute (Incor) University of Sao Paulo, São Paulo, Brazil
Blood Pressure Management in Stroke Following Endovascular Treatment
- Conditions
- Interventions
- First Posted Date
- 2020-07-23
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Hamilton Health Sciences Corporation
- Target Recruit Count
- 30
- Registration Number
- NCT04484350
- Locations
- 🇨🇦
Hamilton General Hospital, Hamilton, Ontario, Canada
Comparing Nifedipine and Enalapril in Medical Resources Used in the Postpartum Period
- Conditions
- Interventions
- First Posted Date
- 2020-01-22
- Last Posted Date
- 2022-11-30
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 94
- Registration Number
- NCT04236258
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy
- Conditions
- Interventions
- First Posted Date
- 2019-12-03
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Region Skane
- Target Recruit Count
- 30
- Registration Number
- NCT04183101
- Locations
- 🇸🇪
Akademiska sjukhuset, Uppsala, Sweden
🇸🇪Region Skåne Skåne Universitetssjukhus, Lund, Sweden
🇸🇪Sahlgrenska Hospital, Gothenburg, Sweden
Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC
- Conditions
- Interventions
- First Posted Date
- 2019-07-17
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 919
- Registration Number
- NCT04023227
- Locations
- 🇲🇽
Novartis Investigative Site, Xalapa, Mexico
Impact of Angiotensin Converting Enzyme Activity on Exercise Training Sensitivity
- Conditions
- Interventions
- First Posted Date
- 2019-05-14
- Last Posted Date
- 2020-11-05
- Lead Sponsor
- University of Copenhagen
- Target Recruit Count
- 52
- Registration Number
- NCT03949075
- Locations
- 🇩🇰
Department of Nutrition, Exercise and Sports, Copenhagen, Denmark
COmparing arNi and Ace For Improving Erectile Dysfunction in mEN With reduCed Ejection Fraction Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2019-04-17
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 27
- Registration Number
- NCT03917459
- Locations
- 🇩🇪
Novartis Investigative Site, Wermsdorf, Germany
Enalapril Maleate on Arterial Stiffness in Rheumatoid Arthritis.
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- University of Guadalajara
- Target Recruit Count
- 59
- Registration Number
- NCT03667131
- Locations
- 🇲🇽
Instituto de Investigación en Reumatología y Sistema Músculo Esquelético, Guadalajara, Jalisco, Mexico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.